ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc (DRNA)

38.22
0.00
( 0.00% )
Actualizado: 18:00:00

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
38.22
Postura de Compra
42.07
Postura de Venta
38.22
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
38.22
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

DRNA Últimas noticias

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through...

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo...

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo...

Direxion Launches mRNA ETF (MSGR)

Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK, Dec. 9, 2021 NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the...

Novo Nordisk to Acquire Dicerna

– Acquisition to Accelerate and Expand Novo Nordisk Development of RNAi Therapeutics Using Dicerna’s Proprietary GalXC™ Technology Platform – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today...

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

– Milestone Triggers Two Single-Digit Multimillion-Dollar Payments to Dicerna – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference...

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

– Belcesiran Was Shown to Be Safe and Well Tolerated in Phase 1 Trial and Demonstrated Robust, Dose-Dependent Reductions in Serum Alpha-1 Antitrypsin –  – Enrollment in ESTRELLA Phase 2 Study of...

Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical...

 Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

 – Nedosiran Achieved Primary Endpoint Demonstrating Statistically Significant Sustained Reduction in Urinary Oxalate Excretion and Showed Robust Efficacy in PH1 – – Real-World Healthcare...

Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SPPLSIMPPLE Ltd
US$ 0.916
(186.25%)
310.91M
NUWENewellis Inc
US$ 2.65
(94.85%)
90.21M
STAFStaffing 360 Solutions Inc
US$ 2.83
(66.47%)
49.42M
ADNAdvent Technologies Holdings Inc
US$ 3.0468
(60.36%)
63.15M
OMICSingular Genomics Systems Inc
US$ 21.2921
(58.19%)
285.17k
FIACFocus Impact Acquisition Corporation
US$ 1.00
(-88.74%)
172
SSPEW Scripps Company
US$ 2.205
(-37.36%)
2.88M
INVZWInnoviz Technologies Ltd
US$ 0.0642
(-33.13%)
2k
GCTKGlucoTrack Inc
US$ 1.20
(-31.03%)
66.88k
ILLRTriller Group Inc
US$ 3.00
(-29.91%)
1.93M
SPPLSIMPPLE Ltd
US$ 0.916
(186.25%)
310.91M
ELABElevai Labs Inc
US$ 0.0203
(-29.76%)
217.37M
SQQQProShares UltraPro Short QQQ
US$ 7.4414
(0.02%)
132.36M
NVDANVIDIA Corporation
US$ 138.1001
(1.99%)
129.99M
PLUGPlug Power Inc
US$ 2.495
(19.38%)
90.35M

DRNA Discussion

Ver más
ok2buy ok2buy 3 años hace
Vindicated on this one today. Being bought out. All cash offer at $38.50/share. Congrats to those who bought and held./ok2
👍️0
ok2buy ok2buy 3 años hace
US politics is driving the market lower in general. The DEMS and the REPUBS need to agree on money required to pay the existing debt and define the debt ceiling (if there is to be one). The market hates uncertainty. IMO, nothing wrong with the company. When the NAZ is moving lower by 300 - 400 points on numerous days you know there is trouble./ok2
👍️0
MomsSpaghetti MomsSpaghetti 3 años hace
That's one heck of a drop... and a lot got stopped up... Thoughts?
👍️0
XenaLives XenaLives 3 años hace
Wow - average share price >$30

Funny how they all report the same average share price.


2021-08-13 13F Rtw Investments, Lp
31.44 7,521,859 0.78 280,716 47.10
2021-08-11 13F BlackRock Inc. 31.45 5,775,534 -5.58 215,543 37.80
2021-08-13 13F Vanguard Group Inc
31.44 3,620,353 1.48 135,112 48.11
2021-08-16 13F Wellington Management Group Llp 31.45 3,299,353 -23.64 123,132 11.45
2021-08-16 13F Bain Capital Life Sciences Investors, LLC 31.44 3,080,237 0.00 114,954 45.95
2021-08-16 13F State Street Corp
31.45 2,589,062 -14.99 96,624 24.08
2021-08-16 13F Price T Rowe Associates Inc /md/ 31.45 1,982,925 17.11 74,003 70.93


https://fintel.io/so/us/drna
👍️0
XenaLives XenaLives 3 años hace
This?


Net Loss – Net loss was $40.8 million, or $0.53 per share, for the second quarter ended June 30, 2021, compared to a net loss of $31.8 million, or $0.43 per share, for the same period in 2020.


https://investors.dicerna.com/node/13526/html
👍️0
XenaLives XenaLives 3 años hace
Trying to figure out why the stock dumped after this PR:


Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Aug 05, 2021


– Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants

more...



https://investors.dicerna.com/news-releases/news-release-details/dicerna-reports-positive-top-line-results-phyoxtm2-pivotal
👍️0
XenaLives XenaLives 3 años hace
Historic short interest:

Thanks for the reminder Red...

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Dicerna Pharmaceuticals, Inc. - Common Stock
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

09/15/2021 4,126,869 0.11 914,655 4.51
08/31/2021 4,122,137 (19.29) 1,163,697 3.54
08/13/2021 5,107,461 9.86 1,938,271 2.64
07/30/2021 4,649,214 (2.20) 630,504 7.37
07/15/2021 4,753,763 19.05 742,954 6.40
06/30/2021 3,993,134 (19.41) 794,900 5.02
06/15/2021 4,954,651 (2.49) 703,160 7.05
05/28/2021 5,080,919 (8.42) 652,085 7.79
05/14/2021 5,547,789 (2.95) 669,937 8.28
04/30/2021 5,716,157 2.64 604,337 9.46
04/15/2021 5,569,312 4.58 510,702 10.91
03/31/2021 5,325,524 3.22 839,178 6.35
03/15/2021 5,159,496 3.86 908,857 5.68
02/26/2021 4,967,839 7.46 657,667 7.55
02/12/2021 4,622,947 (4.76) 631,608 7.32
01/29/2021 4,854,056 (0.06) 814,938 5.96
01/15/2021 4,856,795 (6.76) 685,284 7.09
12/31/2020 5,208,863 (11.94) 620,536 8.39
12/15/2020 5,915,239 1.85 692,346 8.54
11/30/2020 5,807,929 0.68 382,409 15.19
11/13/2020 5,768,562 (0.36) 564,424 10.22
10/30/2020 5,789,376 24.06 602,784 9.60
10/15/2020 4,666,501 (1.74) 428,490 10.89
09/30/2020 4,749,326 22.31 525,176 9.04


👍️0
XenaLives XenaLives 3 años hace
Institutional Shares 69,547,052 - 89.47% (ex 13D/G)

Institutional Ownership and Shareholders
Dicerna Pharmaceuticals Inc (US:DRNA) has 429 institutional owners and shareholders (aka shareholding pattern) that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 69,547,052 shares. Largest shareholders include Rtw Investments, Lp, BlackRock Inc., Vanguard Group Inc, Wellington Management Group Llp, Bain Capital Life Sciences Investors, LLC, State Street Corp, Price T Rowe Associates Inc /md/, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Aquilo Capital Management, LLC, and IWM - iShares Russell 2000 ETF.

Dicerna Pharmaceuticals Inc (US:DRNA) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

https://fintel.io/so/us/drna

👍️0
ok2buy ok2buy 3 años hace
Added again last week on this one. Buy and hold, should move back up. Best of luck to the longs./ok2
👍️0
ok2buy ok2buy 3 años hace
Bought today with the roll back. Institutions own 85 % of the stock. Will hold if necessary, money in the bank./ok2
👍️0
PennyStock Alert PennyStock Alert 5 años hace
will be interesting after the 1/10 with 6.2 mil shares o/s instead of the current 62 mil
👍️0
wiltonio wiltonio 8 años hace
Domain Partners VIII, L.P. has filed a new activist 13D, reporting 14.9% ownership in $DRNA - https://fintel.io/so/us/drna
👍️0
ValueInvestor15 ValueInvestor15 8 años hace
Dicerna Pharma $DRNA has little Margin of Safety for Value Investors before earnings Wednesday:

Fair Value Source
👍️0
Warchest Warchest 8 años hace
+.25 !!
👍️0
Warchest Warchest 8 años hace
chart looking good !!!
👍️0
INTL INTL 8 años hace
Possible breakout
👍️0
ClayTrader ClayTrader 8 años hace
* * $DRNA Video Chart 09-29-16 * *

Link to Video - click here to watch the technical chart video
👍️0
stocktrademan stocktrademan 10 años hace
$DRNA DD Notes ~ http://www.ddnotesmaker.com/DRNA

bullish
quick trade

$DRNA recent news/filings

## source: finance.yahoo.com

Wed, 17 Dec 2014 23:58:56 GMT ~ Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced ...

read full: http://www.noodls.com/view/03BF21AF94C12E65B84F7443AA9F6916484BF35C
*********************************************************

Wed, 17 Dec 2014 23:36:00 GMT ~ Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leader in the development of RNAi-based therapeutics, today announced the appointment of Theodore T.

read full: http://finance.yahoo.com/news/dicerna-announces-appointment-theodore-t-233600639.html
*********************************************************

Mon, 15 Dec 2014 12:12:30 GMT ~ Dicerna R&D Update Webcast Reminder

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, ...

read full: http://www.noodls.com/view/B6D67345529B90360B6D6BAD66985311ACD0E760
*********************************************************

Mon, 15 Dec 2014 12:00:00 GMT ~ Dicerna R&D Update Webcast Reminder

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, announces webcast and conference call information for its previously announced R&D Update webcast later today, December 15, 2014, at 4:30 p.m.

read full: http://finance.yahoo.com/news/dicerna-r-d-webcast-reminder-120000794.html
*********************************************************

Tue, 25 Nov 2014 14:30:15 GMT ~ Dicerna to Present at the 2014 Deutsche Bank BioFEST

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, ...

read full: http://www.noodls.com/view/F9E1C4DA99D749941B37AA7031DE970335309AA9
*********************************************************


$DRNA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$DRNA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/DRNA/company-info
Ticker: $DRNA
OTC Market Place: Not Available
CIK code: not found
Company name: Dicerna Pharmaceuticals, Inc.
Incorporated In:


$DRNA share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$DRNA extra dd links

Company name: Dicerna Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DRNA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DRNA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DRNA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/news - http://finance.yahoo.com/q/h?s=DRNA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DRNA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DRNA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DRNA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dicerna+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dicerna+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dicerna+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DRNA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DRNA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DRNA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DRNA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DRNA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DRNA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DRNA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DRNA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DRNA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DRNA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DRNA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DRNA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DRNA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DRNA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DRNA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DRNA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DRNA



$DRNA DD Notes ~ http://www.ddnotesmaker.com/DRNA
👍️0